Core Insights - Eli Lilly reported Q3 2025 revenue of $17.601 billion, a 54% year-over-year increase, contributing to a total revenue of $45.887 billion for the first nine months of 2025, reflecting a 46% growth [1][3]. Revenue Breakdown - U.S. revenue for the first nine months reached $30.604 billion (+43%), while Europe saw a significant increase to $8.461 billion (+89%). Japan and China reported revenues of $1.478 billion (+18%) and $1.477 billion (+20%), respectively [3][4]. - In Q3 2025, U.S. revenue was $11.3 billion, down 15% in price but up 60% in volume, leading to a total revenue increase of 54% [4]. Product Performance - Key growth drivers included Mounjaro and Verzenio, generating $24.837 billion (+125%) and $4.118 billion (+10%) respectively in the first nine months [5]. - The market share for Eli Lilly's GLP-1 products in the U.S. expanded to 57.9%, compared to 41.7% for Novo Nordisk [5]. R&D Developments - Eli Lilly achieved significant milestones in R&D, including the completion of six Phase III studies for Orforglipron and reaching primary endpoints for Mounjaro in pediatric Type 2 diabetes [7]. - Upcoming regulatory submissions include Orforglipron for obesity and insulin efsitora alfa for Type 2 diabetes [8]. Company Overview - Eli Lilly, founded in 1876, is a leading global pharmaceutical company focused on innovative drug development to improve human health [11].